Phase I/IIa Study of AZD5335 as monotherapy and combination therapy in participants with solid tumors

Trial Identifier: D8990C00001
Sponsor: AstraZeneca
Start Date: June 2023
Primary Completion Date: January 2028
Study Completion Date: January 2028
Condition: Endometriosis; Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Liverpool, AU, 2170
AU Melbourne, AU, 3000
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, ON London, ON, CA, N6A 5W9
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montréal, QC, CA, H4A 3J1
CA, Quebec Montréal, Quebec, CA, H2X 0A9
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Guangzhou, CN, 510000
CN Guangzhou, CN, 510060
CN Jinan, CN, 250117
CN Xi’an, CN, 710061
CN Zhengzhou, CN, 450008
DE Berlin, DE, 13353
DE Essen, DE, 45136
DE Freiburg, DE, 79106
DE Hannover, DE, 30625
DE Leipzig, DE, 04103
DE Mannheim, DE, 68167
DE Regensburg, DE, 93053
ES Barcelona, ES, 8035
ES Madrid, ES, 28041
ES Madrid, ES, 28050
ES Málaga, ES, 29010
GB Cambridge, GB, CB2 0XY
GB Glasgow, Scotland, GB, G12 0YN
GB London, GB, SE1 9RT
GB London, GB, SW3 6JJ
GB Sutton, GB, SM2 5PT
IL Haifa, IL, 3109601
IL Ramat Gan, IL, 52621
JP Hidaka-shi, JP, 350-1298
JP Kashiwa, JP, 227-8577
JP Koto-ku, JP, 135-8550
JP Sunto-gun, JP, 411-8777
JP Tokyo, JP, 104-0045
KR Seoul, KR, 03080
KR Seoul, KR, 06351
TR Ankara, TR, 06200
TR Ankara, TR, 06800
TR Ankara, TR, 06050
TR Istanbul, TR, 34718
TW Taichung, TW, 40705
TW Tainan City, TW, 70403
TW Taipei, TW, 11259
TW Taipei, TW, 10002
US, CA Duarte, CA, US, 91010
US, CA Irvine, CA, US, 92618
US, CO Aurora, CO, US, 80045
US, KY Louisville, KY, US, 40202
US, MA Boston, MA, US, 02114
US, MI Detroit, MI, US, 48201
US, OH Columbus, OH, US, 43201
US, OR Portland, OR, US, 97239
US, RI Providence, RI, US, 02905
US, RI Providence, RI, US, 02903
US, TX Houston, TX, US, 77030
US, VA Fairfax, VA, US, 22031